

Phospho-IRAK1(S376) Antibody
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP3919a

Specification

Phospho-IRAK1(S376) Antibody - Product Information

Application	IF, WB, IHC-P,E
Primary Accession	P51617
Reactivity	Human
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit IgG
Calculated MW	76537

Phospho-IRAK1(S376) Antibody - Additional Information

Gene ID 3654

Other Names

Interleukin-1 receptor-associated kinase 1, IRAK-1, 2.7.11.1, IRAK1, IRAK

Target/Specificity

This Phospho-IRAK1(S376) antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 348-381 amino acids from human IRAK1.

Dilution

IF~~1:25

WB~~1:1000

IHC-P~~1:25

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Phospho-IRAK1(S376) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Phospho-IRAK1(S376) Antibody - Protein Information

Name IRAK1 ([HGNC:6112](#))

Synonyms IRAK

Function Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3.

Cellular Location

Cytoplasm. Nucleus. Lipid droplet Note=Translocates to the nucleus when sumoylated. RSAD2/viperin recruits it to the lipid droplet (By similarity).

Tissue Location


Isoform 1 and isoform 2 are ubiquitously expressed in all tissues examined, with isoform 1 being more strongly expressed than isoform 2.

Phospho-IRAK1(S376) Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Phospho-IRAK1(S376) Antibody - Images




Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervical epithelial adenocarcinoma cell line) cells labeling IRAK1 with AP3919a at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG (NK179883) secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm and nuclear speckles staining on HeLa cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin (PD18466410) at 1/100 dilution (red). The nuclear counter stain is DAPI (blue).



Western blot analysis of lysates from HeLa cell line, untreated or treated with IL-1 beta(20ng/ml) + Calyculin A(100nM), using (Cat. #AP3919a)(upper) or Tubulin (lower).



AP3919a staining IRAK1 in human kidney tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0.5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hour at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.



AP3919a staining IRAK1 in human testis tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0.5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hour at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.

Phospho-IRAK1(S376) Antibody - Background

Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor- signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBK/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3.

Phospho-IRAK1(S376) Antibody - References

Cao Z., et al. *Science* 271:1128-1131(1996).
Reichwald K., et al. *Mamm. Genome* 11:182-190(2000).
Jensen L.E., et al. *J. Biol. Chem.* 276:29037-29044(2001).
Rao N., et al. *Mol. Cell. Biol.* 25:6521-6532(2005).
Ross M.T., et al. *Nature* 434:325-337(2005).